EUVIMEDEUVIMED entdecken
Crossref

Discovery of a Novel Bifunctional Steroid Analog, YXG-158, as an Androgen Receptor Degrader and CYP17A1 Inhibitor for the Treatment of Enzalutamide-Resistant Prostate Cancer

Ao Wang, Xianggang Luo, Xin Meng, Zhengyu Lu, Kaixian Chen, Yushe Yang iD

Journal of Medicinal Chemistry · 27.07.2023 · 66 (14) · 9972-9991

DOI: 10.1021/acs.jmedchem.3c00880 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 17.07.2023. Verfasst von Ao Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. Hauptthemen laut MEDLINE: Receptors, Androgen, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The androgen/androgen receptor (AR) signaling pathway plays an important role in castration-resistant prostate cancer (CRPC). Bifunctional agents that simultaneously degrade AR and inhibit androgen synthesis are expected to block the androgen/AR signaling pathway more thoroughly, demonstrating the promising therapeutic potential for CRPC, even enzalutamide-resistant CRPC. Herein, a series of steroid analogs were designed, synthesized, and identified as selective AR degraders, among which YXG-158 (23-h) was the most potent antitumor compound with dual functions of AR degradation and CYP17A1 inhibition. In addition, 23-h abrogated the hERG inhibition and exhibited excellent PK profiles. In vivo, 23-h effectively inhibited the growth of hormone-sensitive organs in the Hershberger assay and exhibited robust antitumor efficacy both in enzalutamide-sensitive (LNCaP/AR) and enzalutamide-resistant (C4-2b-ENZ) xenograft models. Thus, 23-h was chosen as a preclinical candidate for the treatment of enzalutamide-resistant prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, AndrogenProstatic Neoplasms, Castration-ResistantMaleHumansAndrogensDrug Resistance, NeoplasmCell Line, TumorAndrogen AntagonistsNitrilesEnzyme InhibitorsSteroidsCell ProliferationSteroid 17-alpha-HydroxylaseBenzamidesPhenylthiohydantoin

Substanzen

Receptors, AndrogenAndrogensAndrogen AntagonistsNitrilesEnzyme InhibitorsSteroidsSteroid 17-alpha-HydroxylaseenzalutamideBenzamidesPhenylthiohydantoin

Autor:innen und Institutionen

  • State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.

ORCID-Profile: Yushe Yang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, A., Luo, X., Meng, X., Lu, Z., Chen, K., & Yang, Y. (2023). Discovery of a Novel Bifunctional Steroid Analog, YXG-158, as an Androgen Receptor Degrader and CYP17A1 Inhibitor for the Treatment of Enzalutamide-Resistant Prostate Cancer. Journal of Medicinal Chemistry, 66(14), 9972-9991. https://doi.org/10.1021/acs.jmedchem.3c00880

Vancouver

Wang A, Luo X, Meng X, Lu Z, Chen K, Yang Y. Discovery of a Novel Bifunctional Steroid Analog, YXG-158, as an Androgen Receptor Degrader and CYP17A1 Inhibitor for the Treatment of Enzalutamide-Resistant Prostate Cancer. Journal of Medicinal Chemistry. 2023;66(14):9972-9991. doi:10.1021/acs.jmedchem.3c00880

BibTeX
@article{Wang2023,
  author = {Wang, Ao and Luo, Xianggang and Meng, Xin and Lu, Zhengyu and Chen, Kaixian and Yang, Yushe},
  title = {Discovery of a Novel Bifunctional Steroid Analog, YXG-158, as an Androgen Receptor Degrader and CYP17A1 Inhibitor for the Treatment of Enzalutamide-Resistant Prostate Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  volume = {66},
  number = {14},
  pages = {9972--9991},
  doi = {10.1021/acs.jmedchem.3c00880}
}
Kostenlos starten →